In the past week, ADMA stock has gone down by -7.93%, with a monthly gain of 15.62% and a quarterly surge of 93.28%. The volatility ratio for the week is 3.58%, and the volatility levels for the last 30 days are 3.46% for Adma Biologics Inc The simple moving average for the last 20 days is 0.62% for ADMA stock, with a simple moving average of 92.53% for the last 200 days.
Is It Worth Investing in Adma Biologics Inc (NASDAQ: ADMA) Right Now?
Additionally, the 36-month beta value for ADMA is 0.53. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ADMA is 223.89M and currently, short sellers hold a 3.70% ratio of that float. The average trading volume of ADMA on July 29, 2024 was 3.22M shares.
ADMA) stock’s latest price update
The stock of Adma Biologics Inc (NASDAQ: ADMA) has decreased by -3.80 when compared to last closing price of 13.16. Despite this, the company has experienced a -7.93% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2024-07-27 that ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company’s IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB.
Analysts’ Opinion of ADMA
Many brokerage firms have already submitted their reports for ADMA stocks, with Raymond James repeating the rating for ADMA by listing it as a “Strong Buy.” The predicted price for ADMA in the upcoming period, according to Raymond James is $5 based on the research report published on July 19, 2023 of the previous year 2023.
Mizuho, on the other hand, stated in their research note that they expect to see ADMA reach a price target of $5. The rating they have provided for ADMA stocks is “Buy” according to the report published on October 13th, 2022.
Raymond James gave a rating of “Strong Buy” to ADMA, setting the target price at $5 in the report published on November 11th of the previous year.
ADMA Trading at 13.89% from the 50-Day Moving Average
After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.76% of loss for the given period.
Volatility was left at 3.46%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares surge +15.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.98% upper at present.
During the last 5 trading sessions, ADMA fell by -6.04%, which changed the moving average for the period of 200-days by +287.99% in comparison to the 20-day moving average, which settled at $12.67. In addition, Adma Biologics Inc saw 180.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMA starting from Grossman Adam S, who sale 100,000 shares at the price of $10.72 back on Jun 14 ’24. After this action, Grossman Adam S now owns 2,081,475 shares of Adma Biologics Inc, valued at $1,071,980 using the latest closing price.
ELMS STEVE, the Director of Adma Biologics Inc, sale 411,829 shares at $6.08 during a trade that took place back on Mar 19 ’24, which means that ELMS STEVE is holding 2,115,671 shares at $2,503,920 based on the most recent closing price.
Stock Fundamentals for ADMA
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.39 for the gross margin
The net margin for Adma Biologics Inc stands at -0.01. The total capital return value is set at 0.15. Equity return is now at value -2.43, with -1.05 for asset returns.
Based on Adma Biologics Inc (ADMA), the company’s capital structure generated 0.46 points at debt to capital in total, while cash flow to debt ratio is standing at 0.16. The debt to equity ratio resting at 0.86. The interest coverage ratio of the stock is 1.95.
Currently, EBITDA for the company is 29.96 million with net debt to EBITDA at 1.8. When we switch over and look at the enterprise to sales, we see a ratio of 10.64. The receivables turnover for the company is 5.71for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.21.
Conclusion
In conclusion, Adma Biologics Inc (ADMA) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
